Bayer begins Rs 1.3K crore open offer process to buy up to 26 percent stake in Monsanto India
German chemicals and pharma major Bayer group has launched the process for over Rs 1,300 crore open offer to acquire up to 26 percent additional stake in Monsanto India, following global acquisition of the US biotech major for USD 63 billion.
Bayer AG, along with its Indian arm Bayer CropScience, has proposed to buy up to 44,88,315 shares, representing 26 percent of the fully diluted voting equity share capital of Monsanto India, according to a regulatory filing.
The open offer was triggered as Bayer group has completed the USD 63 billion mega-deal to acquire Monsanto to create the world’s biggest agro-chemical and seed company. The deal resulted in Bayer group indirectly acquiring 72.14 percent stake in Monsanto India Ltd. Bayer group has fixed the open offer price at Rs 2,926.87 per share and the maximum size of the open offer will be Rs 1,313.67 crore, Monsanto India said in the filing to the BSE. The open offer will commence on July 27.
Bayer India had an annual revenue of 600 million euros (about Rs 4,700 crore) in 2017, Richard van der Merwe, the senior Bayer representative, South Asia, had said in January this year. Monsanto is selling genetically modified (GM) cotton seeds in India for more than a decade. With this deal, Monsanto would add seed business to Bayer’s already significant crop science and pharmaceutical business in India.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd